Performance Evaluation of the Biological Diagnosis of HIT
Recruiting
- Conditions
- Heparin-induced Thrombocytopenia (HIT)
- Registration Number
- NCT06180785
- Lead Sponsor
- University Hospital, Strasbourg, France
- Brief Summary
Heparin-induced thrombocytopenia (HIT) is a severe complication of heparin therapy with a non-negligible incidence (estimated at 2.6% of unfractionated heparin treatments and 0.2% of low molecular weight heparin treatments). It is generally secondary to the appearance of IgG antibodies directed against the platelet factor 4 (PF4) - heparin complex. These antibodies, once bound to this complex, are likely to activate platelets: the thrombotic risk generated can be potentially fatal.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 894
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Retrospective description of the biological diagnosis approach for heparin-induced thrombocytopenia (HIT) in the Hematology laboratory of the University Hospitals of Strasbourg through study completion, an average of 1 month
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Laboratoire d'Hématologie - CHU de Strasbourg - France
🇫🇷Strasbourg, France